Naltrexone and buprenorphine combination in the treatment of opioid dependence.
about
Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on AddictionEndogenous opiates and behavior: 2006Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin AFrom research to the real world: buprenorphine in the decade of the Clinical Trials NetworkAlanine analogues of [D-Trp]CJ-15,208: novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour.Opioid dependence treatment: options in pharmacotherapy.The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuseEvaluation of the agonist PET radioligand [¹¹C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242.Management of relapse in naltrexone maintenance for heroin dependence.Advances in opioid antagonist treatment for opioid addiction.Evaluation of opioid modulation in major depressive disorderBuprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.The kappa opioid receptor: from addiction to depression, and back.Test-retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer for the κ opioid receptor.Pharmacological enhancement of naltrexone treatment for opioid dependence: a reviewOpioid detoxification and naltrexone induction strategies: recommendations for clinical practice.C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors.Agonist-antagonist combinations in opioid dependence: a translational approachNovel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us?A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependenceBuprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.Development of κ opioid receptor antagonists.The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208Long-acting injectable naltrexone for the treatment of alcohol dependence.Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.Outcomes among buprenorphine-naloxone primary care patients after Hurricane Sandy.Heroin anticraving medications: a systematic review.Treatment outcome for flexible dosing buprenorphine maintenance treatment.Effect of buprenorphine dose on treatment outcome.Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.Antagonist-agonist combinations as therapies for heroin addiction: back to the future?Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in miceKappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.Favorable mortality profile of naltrexone implants for opiate addiction.A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone.Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice.Genetic association analyses of PDYN polymorphisms with heroin and cocaine addiction.
P2860
Q26770785-D811F92C-38AD-4A74-89CB-4B6F60A112AEQ28752585-8165C09D-94C6-4FD4-89F5-8FF5C132231EQ30467220-AF656D04-ED79-43F5-BE96-D5066823ED5EQ33783274-D0A1E85F-04DC-43C8-BFB9-3FA9135CD261Q33842725-7EBB062D-AC10-49F1-B21A-07A333872CC4Q33868638-B8AA0DAB-FA2D-438E-9923-6395A60C025DQ33890721-34A9866E-9DEF-44CC-9133-BB064FC62015Q34073200-E7B5D9E5-C41F-434B-A11E-FB23206A1F59Q34128519-1DB7F5B7-0EA2-47BE-8B1A-28AF0F8A2E52Q34262649-3D7A039A-3A7C-4310-9237-CB3FC87D2C02Q34454397-4E5CAAF2-2A7A-418F-8F9D-0CD1BB16644CQ34517116-EE23C440-5C60-453C-B688-AD1360DB2EDFQ34650892-50FB2E83-0E80-4E8A-9E86-06A18DEB4355Q35067118-BD229D86-1AFF-46EC-9BBF-65C4840C7F95Q35084340-249A2110-665C-4144-A3CA-1722CAF27285Q35090939-1CD14654-91D6-4678-9A54-1DBD067276E1Q35669185-7A685B51-1E66-4E7D-81A8-713774E3A32BQ35848930-9E437767-7CCC-47B4-9640-C601B50A4EBBQ36104010-0956C53C-BE93-4D12-B450-457D66D56E70Q36110480-56C81FD8-D08D-439C-B77C-3765E2F2DCDBQ36251877-A89192CC-297C-4959-A418-796AECDBD4E3Q36394429-5CBD9484-4EE9-4C12-9C1A-6C7A646E22D6Q36728154-4A26B53A-7D5A-4E67-A86D-9320BED2875EQ36836438-06D19AE7-2601-4E3F-8613-BA14AFA2886CQ36887197-2A2EDCCC-88FF-4FA1-B940-BB370BDC5580Q36972683-06104005-DC10-4667-A1F5-434702CAC679Q37140536-5F842A5F-CDC5-4996-88DD-88B1E82D1D40Q37483673-D12189C4-066D-4772-B3C3-986AE1B30AE7Q37613483-3106F3A0-C579-42CE-B585-A6FDFCC2F615Q37800930-E8827F8E-547E-4769-8BC8-C79EF905BA9BQ37969169-66C8FB27-DE17-44E9-9AC8-514081E93BDFQ37987271-95848177-50B3-4575-8B74-FFD90E3E35F7Q38716082-179AAA79-F6B3-4E83-BC33-70F236AEB19BQ39902056-529ED882-4521-4008-ACB0-3CF85953AEB4Q41537125-88367F75-AED4-4070-9CEE-5EEB2C7F5184Q41639865-5D7E7D84-42E8-42BB-8E9B-27909C52A15DQ43100374-23970347-1D74-4D84-8B51-FF70F446A650Q47282815-58CDDC11-4B98-4A55-86F6-14C1CB791DCDQ47753097-550A7ECC-3E0A-4908-A061-515A9F0B2C9FQ47988659-14263154-4C7D-4300-A685-1A9B464982A3
P2860
Naltrexone and buprenorphine combination in the treatment of opioid dependence.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Naltrexone and buprenorphine combination in the treatment of opioid dependence.
@en
Naltrexone and buprenorphine combination in the treatment of opioid dependence.
@nl
type
label
Naltrexone and buprenorphine combination in the treatment of opioid dependence.
@en
Naltrexone and buprenorphine combination in the treatment of opioid dependence.
@nl
prefLabel
Naltrexone and buprenorphine combination in the treatment of opioid dependence.
@en
Naltrexone and buprenorphine combination in the treatment of opioid dependence.
@nl
P2093
P2860
P356
P1476
Naltrexone and buprenorphine combination in the treatment of opioid dependence.
@en
P2093
P2860
P304
P356
10.1177/0269881106060835
P407
P577
2006-01-09T00:00:00Z